Impact of COVID-19 related policy changes on filling of opioid and benzodiazepine medications

Abstract Background Healthcare access has changed drastically during the COVID-19 pandemic. Elective medical procedures, including routine office visits, were restricted raising concerns regarding opioid and benzodiazepine provider and prescription availability. Objective To examine how the cancellation of elective medical procedures due to COVID-19 impacted the dispensing of opioid and benzodiazepine prescriptions in Texas. Methods Interrupted time series analyses were preformed to examine changes in prescription trends for opioids and benzodiazepines before and after the restriction on elective medical procedures. Samples of patients who filled an opioid or benzodiazepine prescription from January 5, 2020 to May 12, 2020 were identified from the Texas Prescription Monitoring Program. Elective medical procedures were restricted starting March 23, 2020 indicating the beginning of the intervention period. Results Banning elective procedures was associated with a significant decrease in the number of patients (β = −6,029, 95%CI = −8810.40, −3246.72) and prescribers (β = −2,784, 95%CI = −3671.09, −1896.19) filling and writing opioid prescriptions, respectively. Also, the number of patients filling benzodiazepine prescriptions decreased significantly (β = −1,982, 95%CI = −3712.43, −252.14) as did the number of prescribers (β = −708.62, 95%CI = −1190.54, −226.71). Conclusion Restricting elective procedures resulted in a large care gap for patients taking opioid or benzodiazepine prescriptions.